• Optimizing Cancer Assays with JNJ-26854165 (Serdemetan): Pra

  2026-07-25

  This authoritative guide addresses real-world laboratory challenges in cancer research, focusing on the use of JNJ-26854165 (Serdemetan) (SKU A4204). Leveraging scenario-driven Q&A, we demonstrate how this HDM2 antagonist enables reproducible, sensitive cell viability and apoptosis assays. Researchers gain actionable protocols and critical vendor selection insights for reliable results.

• Adipose-Neural Axis Drives Arrhythmia via Leptin-NPY Pathway

  2026-07-24

  Fan et al. (2024) reveal that the interaction between epicardial adipose tissue and cardiac neurons, mediated by leptin and neuropeptide Y (NPY), plays a decisive role in cardiac arrhythmogenesis. Their stem cell-based coculture model identifies the leptin-NPY-Y1R axis as a potential therapeutic target, offering new avenues for cardiovascular and NPY/NPFF system research.

• Breast Cancer’s Dependence on MCL-1: Apoptotic Functions Unv

  2026-07-24

  This article examines recent direct evidence that breast cancer’s reliance on the anti-apoptotic protein MCL-1 stems from its canonical apoptosis inhibition, not non-canonical functions. The findings clarify that targeting MCL-1’s anti-apoptotic activity is essential for effective tumor regression and highlight new opportunities for precision apoptosis research.

• MLN4924 HCl Salt: Optimizing NEDD8-Activating Enzyme Inhibit

  2026-07-23

  MLN4924 HCl salt empowers researchers to precisely dissect neddylation and ubiquitin-mediated protein degradation in advanced cell signaling and cancer models. This guide delivers actionable workflows, troubleshooting strategies, and practical insights from both foundational and cutting-edge studies, enabling robust, reproducible results across diverse experimental contexts.

• Norovirus Exploits NINJ1 for Selective NS1 Protein Secretion

  2026-07-23

  Song et al. reveal that murine norovirus (MNoV) co-opts the host membrane protein NINJ1 to drive the selective secretion of its NS1 protein, providing a mechanistic link between regulated cell death and unconventional viral protein export. These findings advance our understanding of host–pathogen interactions and highlight new facets of membrane rupture beyond bulk DAMP release.

• L-Ornithine in Translational CNS Toxicity: Mechanisms & Guid

  2026-07-22

  Explore how L-Ornithine, a pivotal urea cycle intermediate, bridges ammonia detoxification and central nervous system (CNS) function. This thought-leadership article unpacks the latest mechanistic evidence linking hepatic ornithine dysregulation to astrocyte energy metabolism and neurotoxicity, guiding translational researchers with practical insights and protocol parameters. Drawing on realgar-induced CNS toxicity models and APExBIO’s advanced biochemical standards, we map the competitive landscape, highlight workflow best practices, and outline actionable frontiers in neuro-metabolic research.

• Rotenone as a Mitochondrial Complex I Inhibitor: Experimenta

  2026-07-22

  Rotenone empowers researchers to model mitochondrial dysfunction with precision, enabling advanced investigations into Parkinson's disease and autophagy pathways. APExBIO's validated Rotenone offers unmatched reliability for both in vitro and in vivo neurodegenerative disease research workflows.

• Nutlin-3a (A3671): Reliable MDM2 Inhibitor for Cancer Resear

  2026-07-21

  This article offers an evidence-based, scenario-driven guide to leveraging Nutlin-3a (SKU A3671) for p53 pathway activation, cell cycle arrest, and apoptosis induction in cancer research. Drawing on peer-reviewed literature and practical lab experience, it highlights protocol optimization, data interpretation, and vendor selection for reproducible results. APExBIO’s Nutlin-3a is positioned as a dependable solution for researchers seeking robust MDM2 inhibition.

• Protein-Loaded Polyphosphazene Nanoparticles: Spermine-Drive

  2026-07-21

  The referenced study introduces a robust platform for protein encapsulation using ionic polyphosphazene nanoparticles, crosslinked with spermine tetrahydrochloride. This approach enables enhanced retention of protein activity, improved cellular presentation, and tunable nanoparticle properties, with broad implications for drug delivery and immunotherapy research.

• 3X (DYKDDDDK) Peptide: Maximizing FLAG Tag Purification Powe

  2026-07-20

  The 3X (DYKDDDDK) Peptide supercharges affinity purification and immunodetection of FLAG-tagged proteins, offering unmatched sensitivity and minimal structural interference. Discover protocol upgrades, troubleshooting strategies, and translational insights driven by benchmark studies and APExBIO’s rigorously characterized peptide.

• CKI 7 dihydrochloride: Data-Driven CK1 Inhibition in Cell As

  2026-07-20

  CKI 7 dihydrochloride (SKU B4936) offers biomedical researchers a highly selective, well-characterized Casein kinase 1 inhibitor for reproducible modulation of Wnt signaling, apoptosis, and circadian pathways. By addressing key workflow challenges—such as solubility, specificity, and vendor reliability—CKI 7 dihydrochloride empowers robust data generation in cancer biology and cell viability assays.

• DAF-2 Diacetate: Unraveling Nitric Oxide Dynamics in Senesce

  2026-07-19

  Explore how DAF-2 diacetate enables unparalleled insight into nitric oxide signaling and nodule senescence, leveraging recent breakthroughs. This article offers deep scientific context and protocol clarity for advanced live-cell nitric oxide imaging.

• Caspase 3/7 Drive Cytoprotective Autophagy in Breast Cancer

  2026-07-18

  This study uncovers a non-apoptotic role for caspase 3 and caspase 7 in promoting cytoprotective autophagy and DNA damage response during non-lethal stress in human breast cancer cells. The findings reshape the understanding of caspase function in cancer cell stress adaptation and open new avenues for targeted research.

• Pitavastatin (NK-104): Technical Guidance for Lab Applicatio

  2026-07-17

  Pitavastatin (NK-104) is a high-purity HMG-CoA reductase inhibitor enabling precise inhibition of cholesterol biosynthesis in cellular and biochemical assays. It is optimized for in vitro cardiovascular and atherosclerosis research, but is not validated for clinical or in vivo animal use. Researchers should follow product-specific handling protocols for reproducible results.

• Synthetic Viability with ERCC1 Deficiency in Lung Cancer: Me

  2026-07-17

  This study uncovers how ERCC1 deficiency interacts with p53 status to influence cellular responses to DNA interstrand crosslinks in lung cancer models. The findings clarify why ERCC1 expression alone is insufficient as a clinical biomarker for platinum chemotherapy efficacy, and highlight new roles for DNA-PKcs and BRCA1 in compensatory DNA repair.

449 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page